Enterprise Agreement Notice
These Terms of Service constitute a binding legal agreement between the Customer (the healthcare institution, pharmaceutical company, research organisation, or enterprise entity) and Synthetix Health. They should be reviewed by your legal, compliance, and data protection teams prior to execution.
These Terms operate in conjunction with (a) your executed Data Processing Agreement (DPA), including any EU Standard Contractual Clauses, (b) Business Associate Agreement (BAA), (c) applicable Order Form, and (d) any executed Service Level Agreement (SLA). Section 14.2 sets the order of precedence.
1. Acceptance of Terms
These Terms of Service ("Terms") govern your access to and use of the proprietary clinical intelligence infrastructure, APIs, privacy engine and Clinical Audit Trail (collectively, the "Services") provided by Synthetix Health. The contracting entity is the entity named in your Order Form.
By clicking "I Accept," accessing the platform, executing an Order Form referencing these Terms, or permitting any user within your organisation to access the Services, you agree to be bound by this agreement on behalf of the enterprise, healthcare institution, pharmaceutical company, or research organisation you represent ("Customer" or "you").
Authority Representation
By accepting these Terms, you represent and warrant that: (a) you have full legal authority to bind the Customer entity to this agreement; (b) you have read and understood these Terms; and (c) you agree to these Terms on behalf of the Customer. If you do not have such authority, you must not accept these Terms or use the Services.
These Terms apply globally to all use of the Services, subject to jurisdiction-specific addenda applicable to EU/EEA, US, and Indian operations as described herein.
2. Definitions
| Term | Definition |
|---|---|
| Services | The Synthetix Health clinical intelligence infrastructure, proprietary privacy engine, Clinical Audit Trail, APIs, web application, and all associated platform components. |
| Source Data | Raw clinical data — including EHR records, FHIR-format datasets, clinical trial data, or other healthcare datasets — ingested by the Customer into their dedicated Synthetix instance. |
| Synthetic Data | Mathematically private synthetic healthcare datasets generated by the Synthetix proprietary privacy engine from Source Data, preserving statistical utility while providing formal privacy guarantees. |
| Privacy Certification | The mathematical privacy guarantee accompanying each Synthetic Data output, certifying that outputs meet Synthetix Health's proprietary privacy standard. Parameters and methodology are Confidential Information of Synthetix Health. |
| Clinical Audit Trail | The compliance record kept for every synthetic data release. |
| GDPR | Regulation (EU) 2016/679 (General Data Protection Regulation), including as retained in United Kingdom law (“UK GDPR”). “Controller” and “Processor” have the meanings given in Article 4. |
| EU SCCs | The EU Standard Contractual Clauses (Commission Implementing Decision (EU) 2021/914) and, for United Kingdom transfers, the UK IDTA or Addendum. |
| Data Processing Agreement (DPA) | The data processing agreement governing Synthetix Health's role as Processor under the GDPR / UK GDPR and as Data Processor under the DPDP Act, 2023 and applicable Indian law. |
| Protected Health Information (PHI) | Individually identifiable health information as defined under HIPAA (45 CFR §160.103) transmitted or maintained by a covered entity or business associate. |
| Business Associate Agreement (BAA) | The HIPAA-required agreement executed between Synthetix Health (as Business Associate) and the Customer (as Covered Entity or downstream Business Associate) governing permissible uses and disclosures of PHI. |
| Data Fiduciary / Data Principal | Under the DPDP Act, 2023: Data Fiduciary means the entity determining the purpose and means of data processing; Data Principal means the individual to whom personal data relates. |
| FHIR | Fast Healthcare Interoperability Resources — the international standard for healthcare data exchange (HL7 FHIR R4), natively supported by the Synthetix ingestion pipeline. |
| Re-identification | Any attempt, by any technical or non-technical means, to link, connect, or otherwise associate Synthetic Data outputs with the identity of any individual whose data was represented in the Source Data. |
| Order Form | A mutually executed commercial agreement specifying the Services, compute tier, fees, and any Customer-specific terms. Incorporated by reference. |
| DPDP Act | India's Digital Personal Data Protection Act, 2023. |
| SPDI Rules | India's IT (Reasonable Security Practices and Procedures and Sensitive Personal Data or Information) Rules, 2011. |
3. The Synthetix Infrastructure and Access Grant
3.1 Service Description
Synthetix Health provides compute infrastructure designed to generate mathematically private, high-fidelity Synthetic Data from Source Data utilising proprietary privacy-preserving algorithms. The platform includes:
- Synthesis Workspace: FHIR-native ingestion pipeline, proprietary privacy engine, and multi-format synthetic data export.
- Clinical Audit Trail: A compliance record for every synthetic data release, designed to support GDPR accountability (Article 5(2)), HIPAA audit control requirements (45 CFR §164.312(b)) and DPDP Act accountability obligations.
- APIs and Integrations: RESTful APIs enabling integration with existing EHR systems, research data warehouses, and AI/ML development pipelines.
3.2 Access Grant
Subject to your compliance with these Terms, execution of applicable BAAs and DPAs, and timely payment of fees, Synthetix Health grants you a limited, non-exclusive, non-transferable, non-sublicensable, enterprise-wide right to access and use the Services solely for your internal business, research, and machine learning development purposes during the applicable subscription term.
3.3 Service Levels
Platform uptime targets, support tiers, incident response SLAs, and scheduled maintenance windows are set forth in the applicable Service Level Agreement (SLA) executed with your organisation. In the absence of a separately executed SLA, Synthetix Health will use commercially reasonable efforts to maintain platform availability consistent with its standard enterprise service levels.
3.4 Compliance Infrastructure
The Services are architected to align with GDPR Article 32 and HIPAA Security Rule requirements. For Indian enterprise customers, the platform is aligned with DPDP Act technical safeguard obligations and the ABDM Health Data Management Policy. Specific compliance certifications are set forth in your Order Form.
4. Acceptable Use and Strict Prohibitions
4.1 Permitted Use
You agree to use the Services strictly in accordance with: (a) these Terms; (b) your Order Form; (c) applicable local, national, and international law, including the GDPR and applicable EU/EEA member-state law, HIPAA, the HITECH Act and any applicable state-level health privacy laws in the United States, and the DPDP Act and IT Act in India; and (d) all applicable research ethics requirements governing your research activities, including EU/EEA research ethics committees (in Sweden, the Swedish Ethical Review Authority) and institutional review boards (IRB/IEC).
4.2 Strict Prohibitions
Zero-Tolerance: Re-identification Prohibition
You shall not, under any circumstances, use algorithms, machine learning models, linkage attacks, auxiliary datasets, statistical inference, or any other technical or non-technical method to attempt to re-identify, de-anonymise, or reverse-engineer Synthetic Data to uncover the identity of any individual represented in the Source Data.
This prohibition applies to your organisation, all of your employees, contractors, and agents, and extends to any downstream recipients of Synthetic Data under any data sharing arrangement.
Violation constitutes a material breach resulting in immediate termination with no right to cure, forfeiture of prepaid fees, and potential civil, administrative and criminal liability under the GDPR (administrative fines of up to €20 million or 4% of total worldwide annual turnover, whichever is higher), HIPAA, the HITECH Act, the DPDP Act (penalties of up to approx. €23.5 million / USD 27 million / INR 250 crore; the statutory limit is set in INR), and applicable privacy law.
You explicitly agree NOT to engage in any of the following:
- Unauthorised Source Data: You shall not upload, ingest, or process any Source Data unless you hold the explicit legal right, a valid legal basis and Article 9(2) condition where the GDPR applies, patient consent or authorisation in the form required by HIPAA, the DPDP Act, or applicable law, institutional authorisation, and research ethics approval.
- Reverse Engineering: You may not decompile, disassemble, reverse-engineer, or otherwise attempt to derive the source code, underlying algorithms, privacy parameters, or mathematical models of the Synthetix privacy engine or any component of the Services.
- Unauthorised Disclosure: You may not share, sublicense, distribute, sell, or otherwise make available to any third party access credentials, raw API keys, or any restricted Synthetic Data without prior written consent.
- Competitive Intelligence: You may not use the Services or outputs to build competing privacy infrastructure, benchmark against competing products for public disclosure, or otherwise disadvantage Synthetix Health commercially.
- Prohibited Jurisdictions and Sanctioned Parties: You may not use the Services in violation of EU restrictive measures (sanctions), the EU Dual-Use Regulation (EU) 2021/821, US export control laws (EAR/ITAR), OFAC sanctions, or Indian FEMA restrictions.
- Misrepresentation of Privacy Certification: You may not misrepresent, alter, or remove the privacy certification metadata accompanying Synthetic Data outputs. Synthetic Data must be disclosed with its original privacy certification to any downstream recipients.
4.3 Consequences of Prohibited Use
Material Breach and Enforcement
Any violation of Section 4.2 constitutes a material breach. Synthetix Health reserves the right, without prior notice, to: (a) immediately suspend or terminate your access; (b) preserve and disclose relevant logs and audit trails to regulatory authorities (including EU/EEA supervisory authorities, HHS OCR and MeitY) as required by law; (c) seek injunctive relief and all available legal and equitable remedies.
Data breaches caused by Customer misuse may expose your organisation to administrative fines under the GDPR of up to €20 million or 4% of total worldwide annual turnover, whichever is higher, and to penalties under the DPDP Act, 2023 of up to approx. €23.5 million / USD 27 million / INR 250 crore. Synthetix Health disclaims all liability for penalties arising from Customer misuse.
5. Intellectual Property and Data Ownership
5.1 Synthetix Health Intellectual Property
Synthetix Health retains all right, title, and interest in and to the Services, including the proprietary privacy engine and all underlying algorithms, privacy parameters, and mathematical models, the Clinical Audit Trail, all platform source code, APIs, documentation, and training materials, and all improvements, enhancements, and derivative works.
Nothing in these Terms transfers any ownership of Synthetix Health's intellectual property to you.
5.2 Customer Source Data
You retain all ownership rights, title, and interest in and to your Source Data. Synthetix Health claims no ownership over your Source Data. You grant Synthetix Health a limited, non-exclusive license to access, process, and transmit your Source Data solely to the extent necessary to provide the Services, subject to your BAA and DPA.
You represent and warrant that you own or have the lawful right and all necessary consents, authorisations, and approvals to ingest your Source Data into the Services.
5.3 Synthetic Data Ownership
Upon successful generation and payment of associated compute fees, you own the resulting Synthetic Data generated within your dedicated instance, subject to the following conditions:
- Ownership of Synthetic Data does not include ownership of the algorithms, models, or methods used to generate it;
- Synthetic Data must be used, shared, and disclosed in accordance with Section 4 (Acceptable Use);
- Synthetic Data must be accompanied by its privacy certification and relevant Clinical Audit Trail metadata in any downstream sharing arrangement or publication;
- Synthetix Health retains the right to use aggregated, statistical, and anonymised metadata about synthetic data generation events for platform improvement and research purposes, provided such use does not identify any individual or Customer.
5.4 Trained Models and Derivative Works
AI and machine learning models trained using Synthetic Data generated on the Synthetix platform are entirely your intellectual property. Synthetix Health claims no rights in such models. You acknowledge that the regulatory status of AI models trained on synthetic data (including any CE marking under the EU Medical Device Regulation (EU) 2017/745 and any FDA submissions) is your sole responsibility.
5.5 Feedback
If you provide Synthetix Health with feedback, suggestions, or ideas about the Services ("Feedback"), you grant Synthetix Health a perpetual, irrevocable, royalty-free, worldwide license to use, incorporate, and commercialize such Feedback without restriction. Synthetix Health will not identify you as the source of Feedback without your prior written consent.
6. Security and Compliance
6.1 Synthetix Health Security Obligations
| Security Control | Standard / Commitment |
|---|---|
| GDPR Alignment (EU/EEA & UK) | Technical and organisational measures per GDPR Article 32; processor obligations per Article 28; breach notification support per Articles 33–34 |
| Encryption in Transit | Industry-standard encryption for all data in transit |
| Encryption at Rest | AES-256 for all stored data including Source Data, Synthetic Data, and audit logs |
| Access Controls | Role-based access control (RBAC), MFA, principle of least privilege, logical tenant isolation |
| Audit Logging | Clinical Audit Trail supporting GDPR accountability (Article 5(2)), HIPAA audit control requirements (45 CFR §164.312(b)) and DPDP Act accountability obligations |
| Vulnerability Management | Regular penetration testing, vulnerability scanning, and timely patch management |
| Incident Response | Documented IR plan; breach notification support under GDPR Articles 33–34; breach notification compliant with HIPAA Breach Notification Rule (45 CFR Part 164, Subpart D) and DPDP Act Section 8 |
| Compliance Alignment | GDPR Article 32; HIPAA Security Rule; DPDP Act technical safeguards; ABDM Health Data Management Policy |
6.2 GDPR Data Processing Addendum (EU/EEA and UK)
GDPR DPA — Mandatory Where the GDPR / UK GDPR Applies
If you are established in the EU/EEA or UK, or your Source Data includes personal data of EU/EEA or UK data subjects, the parties will execute a Data Processing Addendum incorporating the requirements of GDPR Article 28(3) — and, where personal data is transferred outside the EEA/UK, the EU Standard Contractual Clauses (Commission Implementing Decision (EU) 2021/914) or the UK IDTA/Addendum — before any such personal data is processed through the Services.
Under the DPA, Synthetix Health acts as Processor and will: (a) process personal data only on your documented instructions as Controller; (b) implement technical and organisational measures consistent with GDPR Article 32; (c) assist you, taking into account the nature of processing, with data subject rights requests (Articles 12–23) and with your obligations under Articles 32–36 (including data protection impact assessments); (d) notify you without undue delay after becoming aware of a personal data breach; (e) engage sub-processors only with authorisation and under equivalent written obligations; and (f) at your choice, delete or return personal data at the end of the engagement.
You, as Controller, remain responsible for: (a) the lawfulness of processing instructed to Synthetix Health (Article 6); (b) establishing a valid Article 9(2) condition for any special-category health data; and (c) providing required notices to data subjects.
6.3 HIPAA Business Associate Agreement (US)
HIPAA BAA — Mandatory for PHI Processing
If your Source Data contains Protected Health Information (PHI) as defined by HIPAA (45 CFR §160.103), you must execute a Business Associate Agreement (BAA) with Synthetix Health before ingesting any PHI into the Services.
Synthetix Health, as Business Associate, will: (a) use and disclose PHI only as permitted by the BAA and HIPAA; (b) implement safeguards required under the HIPAA Security Rule; (c) report breaches of unsecured PHI within the timeframes required by the HIPAA Breach Notification Rule; (d) make its books and records available to HHS for compliance review as required under HITECH.
You, as Covered Entity or upstream Business Associate, remain responsible for: (a) obtaining valid HIPAA-compliant patient authorisations or satisfying an applicable exception prior to sharing PHI; (b) configuring your instance in compliance with your own HIPAA obligations; (c) notifying affected individuals and HHS of breaches in accordance with your own breach notification obligations.
6.4 Data Processing Agreement (India — DPDP Act)
DPDP Act DPA — Mandatory for Indian Enterprise Customers
If you are an Indian enterprise processing personal data (including health data) through the Services, you must execute a Data Processing Agreement (DPA) with Synthetix Health prior to processing.
Synthetix Health acts as Data Processor processing personal data solely on your documented instructions as Data Fiduciary. Synthetix Health commits to: (a) process personal data only for purposes specified in the DPA; (b) implement technical and organisational measures consistent with DPDP Act Section 8; (c) assist you in fulfilling obligations to Data Principals (including rights requests under Sections 11-14); (d) promptly notify you of any personal data breach.
You, as Data Fiduciary, remain responsible for: (a) obtaining valid consent from Data Principals; (b) providing notice to Data Principals that their data will be processed by Synthetix Health; (c) ensuring the lawful basis for all processing instructed to Synthetix Health.
6.5 ABDM and Health Data Standards (India)
For Indian healthcare enterprise customers, Synthetix Health's processing pipeline aligns with:
- The Ayushman Bharat Digital Mission (ABDM) Health Data Management Policy, including consent architecture principles and data minimisation standards;
- The Ministry of Health and Family Welfare (MoHFW) EHR Standards, 2016, with respect to FHIR-format data ingestion and processing;
- The National Health Authority (NHA) guidelines on secondary use of health data, to the extent applicable to synthetic data generation.
6.6 Customer Security Responsibilities
Synthetix Health provides compute infrastructure; you dictate the data flows. You are responsible for:
- Securely configuring your instance, including access controls and network configuration;
- Managing and safeguarding the credentials of all authorised users;
- Ensuring all Source Data ingested meets the legal, consent, and research ethics requirements;
- Promptly notifying Synthetix Health of any suspected unauthorised access or security incident at legal@synthetixhealth.com.
6.7 EU Health Data and AI Rules
Where they apply to your use of the Services or of Synthetic Data, you remain responsible for your own obligations under:
- The European Health Data Space Regulation (EU) 2025/327, including its rules on secondary use of electronic health data;
- The EU AI Act (Regulation (EU) 2024/1689), as amended, including its data governance requirements for AI systems you build or deploy;
- The EU Medical Device Regulation (EU) 2017/745, for any product you develop using Synthetic Data;
- National law implementing the NIS2 Directive (EU) 2022/2555 — in Sweden, the Cybersecurity Act (2025:1506). On reasonable request, Synthetix Health will provide information you need for your supply-chain security obligations;
- National health data and research ethics law — in Sweden, including the Patient Data Act (2008:355) and the Ethical Review Act (2003:460).
Nothing in these Terms is a statement that the Services or Synthetic Data satisfy these rules for your use case.
7. Fees, Billing, and Payment
7.1 Compute and Licensing Fees
Access to the Services is billed according to the compute tier, instance size, API call volume, or subscription model specified in your Order Form. Fees are due in euros (EUR) unless your Order Form specifies US dollars (USD) or Indian rupees (INR), and are payable within thirty (30) days of invoice date unless otherwise agreed.
7.2 Taxes
All fees are exclusive of applicable taxes, levies, duties, or withholdings. You are responsible for payment of all such taxes, including:
- EU Value Added Tax (VAT): Where applicable, including under the reverse-charge mechanism for business customers in the EU/EEA. You must provide a valid VAT identification number where you hold one.
- US Sales and Use Tax: Where applicable under US federal and state law.
- Goods and Services Tax (GST): Where applicable under the Indian GST Act, 2017. Indian customers will receive compliant GST invoices.
- Withholding Tax (India): If Indian tax law requires withholding at source, you shall provide Synthetix Health with valid withholding tax certificates (Form 16A or equivalent) within the period required by law.
7.3 Late Payments
Undisputed invoices not paid within thirty (30) days may accrue interest at the lower of 1.5% per month or the maximum rate permitted by applicable law. Synthetix Health reserves the right to suspend access upon thirty (30) days' prior written notice for non-payment.
7.4 Disputed Invoices
If you dispute any portion of an invoice in good faith, you must notify Synthetix Health in writing within fifteen (15) days of the invoice date. Undisputed portions must be paid by the due date. The parties will work in good faith to resolve billing disputes within thirty (30) days.
8. Term, Suspension, and Termination
8.1 Term
These Terms commence on the date you first accept them (or execute an Order Form referencing them) and continue for the subscription term specified in your Order Form, unless earlier terminated.
8.2 Termination for Convenience
Either party may terminate these Terms or any Order Form by providing sixty (60) days' prior written notice, unless a different period is specified in the relevant Order Form.
8.3 Termination for Cause
Either party may terminate immediately upon written notice if the other party:
- Materially breaches and fails to cure within thirty (30) days of notice (except Section 4.2, 6.2 and 6.3 breaches which carry no right to cure and result in immediate termination);
- Becomes insolvent, makes a general assignment for creditors, or becomes subject to bankruptcy or similar proceedings; or
- In Synthetix Health's reasonable judgment, creates material legal, regulatory, or reputational risk.
8.4 Effect of Termination
Upon termination or expiration:
- Your access to the Services will be revoked;
- You must promptly destroy or return all Synthetic Data, unless you retain an independent right under a separate data sharing agreement;
- The Clinical Audit Trail is a compliance record separate from Source Data and Customer personal data. It contains no Source Data, is not subject to deletion or return under Section 6.2, and is retained for a minimum of six (6) years;
- Sections 2, 4.2, 5, 9, 10, 11, 12, and 13 survive termination.
8.5 Switching and Exit (EU Data Act)
Where Regulation (EU) 2023/2854 (the Data Act) applies to the Services, you may start switching to another provider or to on-premises infrastructure on no more than two (2) months' notice, which replaces any longer notice period in these Terms or your Order Form. Synthetix Health will then:
- Provide a transitional period of thirty (30) calendar days, extendable up to seven (7) months where a shorter period is technically unfeasible;
- Give reasonable assistance, act with due care to maintain continuity, and keep the Services secure during the switch;
- Make exportable data available for retrieval for at least thirty (30) calendar days after the transitional period ends. Exportable data means Source Data you ingested, Synthetic Data generated for you, its privacy certification metadata, and configuration you provided;
- Exclude from export the algorithms, models, privacy parameters and other trade secrets of Synthetix Health;
- Charge no switching charges from 12 January 2027. Before that date, any switching charges will not exceed the costs directly incurred in the switch.
Once the retrieval period ends, Synthetix Health will erase exportable data from the Services, subject to Section 8.4 for the Clinical Audit Trail.
9. Disclaimers
As-Is Infrastructure
THE SERVICES ARE PROVIDED ON AN "AS IS" AND "AS AVAILABLE" BASIS. WHILE OUR PROPRIETARY PRIVACY ENGINE IS MATHEMATICALLY BOUNDED TO PROVIDE FORMAL PRIVACY GUARANTEES, SYNTHETIX HEALTH MAKES NO WARRANTY, EXPRESS OR IMPLIED, THAT:
(a) THE SYNTHETIC DATA WILL GUARANTEE SPECIFIC CLINICAL OUTCOMES, REGULATORY APPROVALS (INCLUDING CE MARKING, FDA CLEARANCE, OR CDSCO APPROVAL), OR AI MODEL PERFORMANCE FOR YOUR SPECIFIC USE CASE;
(b) THE SERVICES WILL BE UNINTERRUPTED, ERROR-FREE, OR FREE FROM SECURITY VULNERABILITIES;
(c) THE SERVICES WILL MEET ALL REQUIREMENTS OF EVERY APPLICABLE JURISDICTION;
(d) THE PRIVACY GUARANTEES WILL SATISFY EVERY POSSIBLE LEGAL OR REGULATORY DEFINITION OF DE-IDENTIFICATION IN EVERY JURISDICTION.
Synthetix Health does not warrant that Synthetic Data is anonymous information under the GDPR (Recital 26) for all use cases. Whether a release is anonymous depends on that release, its context and the means reasonably likely to be used to identify individuals. Customers, as Controllers, are responsible for their own assessment.
Synthetix Health does not warrant that Synthetic Data constitutes "de-identified information" under HIPAA's Safe Harbor or Expert Determination methods (45 CFR §164.514) for all use cases. Customers are responsible for independently determining whether Synthetic Data meets the applicable de-identification standard for their specific regulatory context.
10. Limitation of Liability
10.1 Aggregate Liability Cap
TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, SYNTHETIX HEALTH'S AGGREGATE LIABILITY ARISING OUT OF OR RELATED TO THESE TERMS SHALL NOT EXCEED THE TOTAL FEES PAID BY CUSTOMER IN THE TWELVE (12) MONTHS IMMEDIATELY PRECEDING THE EVENT GIVING RISE TO THE CLAIM.
10.2 Exclusion of Consequential Damages
TO THE MAXIMUM EXTENT PERMITTED BY LAW, IN NO EVENT SHALL EITHER PARTY BE LIABLE FOR ANY INDIRECT, INCIDENTAL, SPECIAL, EXEMPLARY, PUNITIVE, OR CONSEQUENTIAL DAMAGES, INCLUDING LOSS OF REVENUE, PROFITS, BUSINESS, DATA, GOODWILL, OR COST OF SUBSTITUTE SERVICES, EVEN IF ADVISED OF THE POSSIBILITY.
10.3 Jurisdiction-Specific Considerations
- GDPR / UK GDPR (EU/EEA and UK): Nothing in these Terms limits either party's liability to data subjects under GDPR Article 82, or any liability that cannot be limited under mandatory law, including Swedish law where it applies.
- HIPAA / HITECH (US): The liability cap does not limit either party's obligations arising directly under the executed BAA.
- DPDP Act (India): The DPDP Act imposes penalties of up to approx. €23.5 million / USD 27 million / INR 250 crore on Data Fiduciaries. Nothing in these Terms limits Synthetix Health's ability to seek indemnification from Customer for penalties arising from Customer's breach of Data Fiduciary obligations. The IT Act, 2000 (Section 43A) imposes liability for negligent security practices; parties retain their respective obligations.
- Consumer Protection Act, 2019 (India): To the extent any provision conflicts with mandatory consumer protections, such protections prevail. These Terms are, however, B2B enterprise agreements.
11. Indemnification
11.1 Customer Indemnification
Customer shall indemnify, defend, and hold harmless Synthetix Health from any claims, liabilities, damages, penalties, fines, and costs arising out of:
- Customer's breach of these Terms, including violations of Section 4.2;
- Customer's breach of BAA or DPA obligations;
- Failure to establish a valid legal basis or to obtain valid consents, authorisations, or research ethics approvals;
- Regulatory actions arising from Customer's misuse or non-compliance;
- Third-party claims arising from Customer's use of Synthetic Data.
11.2 Synthetix Health Indemnification
Synthetix Health shall indemnify Customer from third-party claims that the Services infringe any patent, copyright, or trade secret; provided that Customer: (a) promptly notifies Synthetix Health; (b) grants sole control of the defence; and (c) provides reasonable cooperation. This indemnity does not apply to claims arising from Customer's modification or combination with third-party materials.
12. Confidentiality
Each party agrees to: (a) hold Confidential Information in strict confidence using no less care than it uses to protect its own; (b) use it solely for purposes of exercising rights or fulfilling obligations under these Terms; and (c) not disclose it without prior written consent, except to employees, contractors, and advisors bound by equivalent confidentiality obligations.
Confidential Information does not include information that: (a) is or becomes publicly known through no fault of the receiving party; (b) was rightfully known prior to disclosure; (c) is independently developed without reference to it; or (d) is required to be disclosed by law, court order, or regulatory authority.
The Clinical Audit Trail, privacy engine architecture, all privacy parameters and mathematical models, and all technical implementation details of the Services are proprietary Confidential Information of Synthetix Health. Customer agrees not to disclose, publish, or reverse-engineer these parameters except as required for regulatory disclosure.
13. Governing Law and Dispute Resolution
13.1 Default Governing Law and Venue
Unless Section 13.2 or 13.3 applies, or your Order Form states otherwise, these Terms are governed by the laws of Sweden, and the parties submit to the exclusive jurisdiction of the courts of Stockholm, Sweden, subject to Section 13.4.
Nothing in these Terms limits any right or obligation arising under the GDPR / UK GDPR or other data protection law that cannot be derogated from by contract, nor either party’s right to lodge complaints with, or cooperate with, EU/EEA supervisory authorities (including Integritetsskyddsmyndigheten (IMY) in Sweden), the European Data Protection Board, or the UK Information Commissioner’s Office.
13.2 US Customers
For customers primarily located in or operating under US law: governed by the laws of the State of Delaware, USA, without regard to conflict of law provisions. Legal actions shall be brought exclusively in Delaware state or federal courts.
13.3 Indian Customers
For customers primarily located in India: governed by the laws of India. Legal actions shall be brought exclusively in the courts of competent jurisdiction in Bangalore, Karnataka, India.
13.4 Cross-Border Disputes
International Arbitration Clause
For disputes involving operations in more than one of the EU/EEA, the United States and India, the parties agree to binding arbitration administered by the SCC Arbitration Institute (the Arbitration Institute of the Stockholm Chamber of Commerce) under its Arbitration Rules, with the seat in Stockholm, Sweden and proceedings in English.
This does not prevent either party from seeking emergency injunctive or interim relief to protect intellectual property, Confidential Information, or to prevent imminent breach of the re-identification prohibition (Section 4.2).
Nothing limits Synthetix Health's ability to file complaints with EU/EEA supervisory authorities, HHS OCR, MeitY, the Data Protection Board of India, or any other competent regulatory authority.
13.5 Compliance with Regulatory Bodies
Each party agrees to cooperate fully with EU/EEA supervisory authorities (including IMY), the UK Information Commissioner’s Office, HHS and its Office for Civil Rights (OCR), MeitY, the Data Protection Board of India (DPBI), and any other competent regulatory authority with jurisdiction.
14. General Provisions
14.1 Entire Agreement
These Terms, together with all executed Order Forms, BAAs, DPAs, and SLAs, constitute the entire agreement and supersede all prior agreements, understandings, and representations.
14.2 Order of Precedence
In the event of conflict: (1) the EU SCCs, where they apply; (2) the DPA (for personal data matters) and the BAA (for PHI-related matters); (3) applicable Order Form; (4) applicable SLA; (5) these Terms of Service.
14.3 Amendments
Synthetix Health may update these Terms. For material changes, we will provide at least thirty (30) days' advance notice via email and in-platform notification. Continued use after the effective date constitutes acceptance.
14.4 Assignment
You may not assign without Synthetix Health's prior written consent. Synthetix Health may assign in connection with a merger, acquisition, or sale of assets, provided the successor assumes all obligations.
14.5 Severability
If any provision is held invalid, it shall be modified to the minimum extent necessary to make it enforceable, and the remaining provisions shall continue in full force.
14.6 Waiver
No failure or delay in exercising any right constitutes a waiver. A waiver of any particular breach does not waive any subsequent breach.
14.7 Force Majeure
Neither party shall be liable for delays caused by events beyond reasonable control, including acts of God, pandemics, government actions, cyberattacks, or telecommunications failures — provided the affected party promptly notifies the other and takes reasonable steps to mitigate.
14.8 Notices
All legal notices must be in writing and delivered by: (a) email to legal@synthetixhealth.com with confirmed receipt; (b) nationally recognised overnight courier; or (c) registered post with acknowledgment.
14.9 Export Controls and Sanctions
You represent and warrant compliance with all applicable EU restrictive measures and export control rules, US export control laws, OFAC sanctions, and Indian FEMA regulations. You may not process data of sanctioned parties without all required licenses.
14.10 Anti-Bribery and Corruption
Both parties agree to comply with all applicable anti-bribery laws, including Chapter 10 of the Swedish Penal Code (Brottsbalken), the US Foreign Corrupt Practices Act (FCPA) and India's Prevention of Corruption Act, 1988.
15. Contact Information
Synthetix Health — Legal and Compliance
Email: legal@synthetixhealth.com
Subject Line Format: [Legal Notice | DPA Request | BAA Request | Compliance Inquiry | Dispute Notice] — [Customer Name] — [Brief Description]
For GDPR matters: Include "GDPR" in the subject line. For HIPAA-related matters: Include "HIPAA" in the subject line. For DPDP Act matters: Include "DPDP" in the subject line.
Response Commitment: Legal notices acknowledged within 2 business days; BAA and DPA execution initiated within 5 business days of request.
Appendix A: Summary of Key Regulatory Obligations
| Regulatory Area | Customer Obligation | Synthetix Health Commitment |
|---|---|---|
| GDPR / UK GDPR (EU/EEA & UK) | Execute the GDPR DPA before processing EU/EEA or UK personal data; establish lawful basis and Article 9(2) condition as Controller | Process only on documented instructions; Article 32 safeguards; breach notification without undue delay; sub-processor flow-down |
| EU Data Act (Switching) | Give notice and plan your switch under Section 8.5 | Support switching and export; no switching charges from 12 January 2027 |
| HIPAA PHI Ingestion (US) | Execute BAA prior to ingesting PHI; obtain valid authorisations; notify of breaches | Provide BAA; implement HIPAA Security Rule safeguards; breach notification within required timeframes |
| CCPA / CPRA (California) | Comply with CCPA obligations as Covered Business | Process California PI only as instructed; support CCPA rights fulfilment |
| DPDP Act 2023 (India) | Act as Data Fiduciary; obtain consent; provide DPDP-compliant notice; execute DPA | Act as Data Processor; process only on Customer instructions; assist with Data Principal rights; implement DPDP technical safeguards |
| SPDI Rules 2011 (India) | Provide prior written consent for SPDI; ensure authorisation | Apply heightened protections; not share SPDI without specific consent |
| ABDM Compliance (India) | Ensure patient consent aligns with ABDM architecture | Align processing with ABDM Health Data Management Policy and NHA guidelines |
| IRB / Ethics Approval | Obtain research ethics approval (EU/EEA ethics committee), IRB (US) or IEC (India) approval for research using synthetic data | Provide privacy certification documentation for regulatory submissions |
| Re-identification Prohibition | Zero-tolerance — see Section 4.2 | Mathematically bound outputs to certified privacy standard; Clinical Audit Trail records all events |
| Export Controls | Ensure no use involving sanctioned parties; obtain licenses | Comply with EU restrictive measures, OFAC and BIS rules; flag jurisdictional restrictions |
Synthetix Health · legal@synthetixhealth.com · Version 3.0 · Effective 4 November 2026